Literature DB >> 25339292

Pathophysiological, cardiovascular and neuroendocrine changes in hypertensive patients during the hemodialysis session.

O A Gutiérrez-Adrianzén1, M E A Moraes2, A P Almeida1, J W O Lima3, M F Marinho1, A L Marques1, J P V Madeiro1, L Nepomuceno1, J M S da Silva1, G B Silva4, E F Daher1, C R M Rodrigues Sobrinho1.   

Abstract

The pathophysiological mechanisms of arterial hypertension during hemodialysis (HD) in patients with end-stage renal disease (ESRD) are still poorly understood. The aim of this study is to investigate physiological, cardiovascular and neuroendocrine changes in patients with ESRD and its correlation with changes in blood pressure (BP) during the HD session. The present study included 21 patients with ESRD undergoing chronic HD treatment. Group A (study) consisted of patients who had BP increase and group B (control) consisted of those who had BP reduction during HD session. Echocardiograms were performed during the HD session to evaluate cardiac output (CO) and systemic vascular resistance (SVR). Before and after the HD session, blood samples were collected to measure brain natriuretic peptide (BNP), catecholamines, endothelin-1 (ET-1), nitric oxide (NO), electrolytes, hematocrit, albumin and nitrogen substances. The mean age of the studied patients was 43 ± 4.9 years, and 54.6% were males. SVR significantly increased in group A (P<0.001). There were no differences in the values of BNP, NO, adrenalin, dopamin and noradrenalin, before and after dialysis, between the two groups. The mean value of ET-1, post HD, was 25.9 pg ml(-1) in group A and 13.3 pg ml(-1) in group B (P = < 0.001). Patients with ESRD showed different hemodynamic patterns during the HD session, with significant BP increase in group A, caused by an increase in SVR possibly due to endothelial dysfunction, evidenced by an increase in serum ET-1 levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339292     DOI: 10.1038/jhh.2014.93

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  24 in total

1.  Physiological changes during hemodialysis in patients with intradialysis hypertension.

Authors:  K-J Chou; P-T Lee; C-L Chen; C-W Chiou; C-Y Hsu; H-M Chung; C-P Liu; H-C Fang
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

Review 2.  Rise in blood pressure during hemodialysis-ultrafiltration: a "paradoxical" phenomenon?

Authors:  E J Dorhout Mees
Journal:  Int J Artif Organs       Date:  1996-10       Impact factor: 1.595

3.  Catecholamines in peripheral venous plasma in patients on chronic haemodialysis.

Authors:  B P McGrath; J G Ledingham; C R Benedict
Journal:  Clin Sci Mol Med       Date:  1978-07

4.  'Paradoxical' rise in blood pressure during ultrafiltration in dialysis patients.

Authors:  M Cirit; F Akçiçek; E Terzioğlu; C Soydaş; E Ok; C F Ozbaşli; A Başçi; E J Mees
Journal:  Nephrol Dial Transplant       Date:  1995       Impact factor: 5.992

5.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

Authors:  J T Kielstein; R H Böger; S M Bode-Böger; J Schäffer; M Barbey; K M Koch; J C Frölich
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

6.  Local angiotensin formation in hindlimbs of uremic hypertensive and renovascular hypertensive rats.

Authors:  M Kuczera; K F Hilgers; C Lisson; D Ganten; U Hilgenfeldt; E Ritz; J F Mann
Journal:  J Hypertens       Date:  1991-01       Impact factor: 4.844

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study.

Authors:  Jula K Inrig; Uptal D Patel; Robert D Toto; Lynda A Szczech
Journal:  Am J Kidney Dis       Date:  2009-07-30       Impact factor: 8.860

9.  Assessment of blood pressure in hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Semin Dial       Date:  2002 Sep-Oct       Impact factor: 3.455

10.  Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans.

Authors:  W G Haynes; C J Ferro; K P O'Kane; D Somerville; C C Lomax; D J Webb
Journal:  Circulation       Date:  1996-05-15       Impact factor: 29.690

View more
  4 in total

Review 1.  Pathophysiology and implications of intradialytic hypertension.

Authors:  Peter Noel Van Buren
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-07       Impact factor: 2.894

2.  Hemodialysis patients with intradialytic rise in blood pressure display higher baseline aortic stiffness and negligible drop in augmentation index with dialysis.

Authors:  Panagiotis I Georgianos; Fani Mpoutsiouki; Erasmia Sabani; Dimitrios N Stamatiadis; Vassilios Liakopoulos; Elias V Balaskas; Pantelis E Zebekakis; Pantelis A Sarafidis
Journal:  Int Urol Nephrol       Date:  2016-01-14       Impact factor: 2.370

Review 3.  Hypertension in patients on dialysis: diagnosis, mechanisms, and management.

Authors:  Sérgio Gardano Elias Bucharles; Krissia K S Wallbach; Thyago Proença de Moraes; Roberto Pecoits-Filho
Journal:  J Bras Nefrol       Date:  2018-11-08

Review 4.  Management of acute intradialytic cardiovascular complications: Updated overview (Review).

Authors:  Delia Timofte; Maria-Daniela Tanasescu; Daniela Gabriela Balan; Adrian Tulin; Ovidiu Stiru; Ileana Adela Vacaroiu; Andrada Mihai; Cristian Constantin Popa; Cristina-Ileana Cosconel; Mihaly Enyedi; Daniela Miricescu; Raluca Ioana Papacocea; Dorin Ionescu
Journal:  Exp Ther Med       Date:  2021-01-26       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.